Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-01-2016 | Award Amount: 15.04M | Year: 2017
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations. MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of 37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions. To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response. MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.
News Article | November 11, 2016
ReportsnReports.com adds "Polycystic Kidney Disease - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Polycystic Kidney Disease with 29 market data tables and 16 figures, spread across 87 pages is available at http://www.reportsnreports.com/reports/743483-polycystic-kidney-disease-pipeline-review-h2-2016.html . Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. Companies discussed in this Polycystic Kidney Disease Pipeline Review, H2 2016 report include Angion Biomedica Corp., Aptevo Therapeutics Inc, DiscoveryBiomed, Inc., Endocyte, Inc., IC-MedTech, Inc., Ipsen S.A. , Kadmon Corporation, LLC, ManRos Therapeutics, Metabolic Solutions Development Company, LLC, NovaTarg Therapeutics, Inc, Otsuka Holdings Co., Ltd. and XORTX Pharma Corp. Drug profiles mentioned in this research report are (ascorbic acid + menadione), ANG-3070, CIM-2, CR-8, DBM-43H11, Drugs for Polycystic Kidney Disease, EC-0371, JP-153, lanreotide acetate, menadione sodium bisulfite, MSDC-0160, MSDC-0602, oxypurinol, pyrimethamine, Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease, Small Molecules to Activate AMPK for Polycystic Kidney Disease, Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors, Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease, STA-2842, tesevatinib tosylate, TNFR x TWEAKR and tolvaptan. The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 11 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Polycystic Kidney Disease. Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Another newly published market research report titled on Kidney Transplant Rejection - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Kidney Transplant Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplant Rejection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alexion Pharmaceuticals Inc, Amgen Inc., Amyndas Pharmaceuticals LLC, Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Astellas Pharma Inc., Bio-inRen, Biogen Inc, Catalyst Biosciences, Inc., Corline Biomedical AB, CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A., Hansa Medical AB, Kyowa Hakko Kirin Co., Ltd., Mabtech Limited, Magnus Life Ltd, Noorik Biopharmaceuticals AG, Novartis AG, Opsona Therapeutics Limited, OSE Immunotherapeutics, Pharmicell Co., Ltd., Pharming Group N.V., Prolong Pharmaceuticals, LLC, Quark Pharmaceuticals, Inc., Shire Plc and Tiziana Life Sciences Plc. Kidney Transplant Rejection Pipeline market research report of 174 pages is available at http://www.reportsnreports.com/reports/743419-kidney-transplant-rejection-pipeline-review-h2-2016.html . ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on: Facebook:https://www.facebook.com/ReportsnReports/ LinkedIn: https://www.linkedin.com/company/reportsnreports Twitter: https://twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Dahlman-Hoglund A.,Sahlgrenska University Hospital |
Renstrom A.,Karolinska Institutet |
Larsson P.H.,Mabtech AB |
Elsayed S.,University of Bergen |
Andersson E.,Sahlgrenska University Hospital
American Journal of Industrial Medicine | Year: 2012
Background: This investigation was triggered by three cases of asthma-about 10% of the workforce-occurring in a salmon processing plant over a short period of time. The aim of the investigation was to characterize the work exposure of inhalable organic particles with personal measurements. Respiratory symptoms at work among workers were also assessed. Methods: Exposures to airborne salmon allergen, airborne mold spores, and endotoxin in water and air were measured during work. To assess the Atlantic salmon (Salmo salar) Sal s 1 allergen exposure a polyclonal sandwich enzyme-linked immunosorbent assay (ELISA) was developed. Current workers (n=26) answered questionnaires and underwent allergy and lung function tests. Results: Using the sensitive ELISA method (0.05ng/ml), we found that workers were exposed to high levels of salmon major allergen at the filleting machine and at the filleting table. Airborne endotoxin levels were low, and mold levels were elevated. Only the three initial asthma cases had IgE to salmon. Of the other workers, 65% reported respiratory symptoms at work. These had lower pulmonary function than workers without such symptoms. Conclusions: We developed a sensitive method to measure salmon antigen in air and found that filleting workers were most exposed. It is important to reduce aerosols by improving the ventilation system, machines and organization of work since respiratory symptoms at work among workers were common. © 2012 Wiley Periodicals, Inc.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.4.3-4 | Award Amount: 3.94M | Year: 2008
Obesity represents the major risk factor for the cardiometabolic syndrome, which is an epidemic disease that generates a severe global socio-economic burden for the public health systems. Enhanced production of proinflammatory adipocytokines by expanded adipose tissue is now considered as a key event in the pathogenesis of this syndrome. This process involves i) the systemic release of adipokines, preferentially by visceral abdominal fat and ii) the paracrine, adipokine-mediated crosstalk between periorganic fat and different organs including skeletal and cardiac muscle. Members of the ADAPT consortium have pioneered this novel view of adipose tissue as an active endocrine organ. However, there is very limited knowledge if adipokines and their downstream signalling pathways may represent drugable targets potentially opening new avenues to combat the devastating complications linked to obesity and the cardiometabolic syndrome. Therefore, the major goal of this project is to identify novel or existing adipocytokines as drug targets that could be used to reverse obesity-associated inflammation and adverse reactions related to excess fat, as outlined in the work programme. For this purpose the mustidisciplinary ADAPT consortium has been formed which integrates basic and clinical science, bioinformatics, in silico drug design and the specific expertise of a large pharmaceutical company. To reach the objectives, a stepwise strategy will be used including i) the identification of novel adipocytokines and the cellular sources and regulation of adipokine production, ii) the analysis of intraorgan crosstalk within adipose tissue which plays a pivotal role in adipose tissue inflammation, iii) the assessment of interorgan crosstalk with a focus on skeletal and cardiac muscle and the role of brown fat and iv) the pharmacological and clinical evaluation of adipokines as drug targets and potential biomarkers.
News Article | December 6, 2016
This report studies Cancer Angiogenesis Inhibitor in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Biocon Allergan CASI Pharmaceuticals Novartis Pfizer Roche Celgene Corporation Levolta Pharmaceuticals Philogen Mabtech Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Cancer Angiogenesis Inhibitor in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by application, this report focuses on consumption, market share and growth rate of Cancer Angiogenesis Inhibitor in each application, can be divided into Application 1 Application 2 Application 3 Global Cancer Angiogenesis Inhibitor Market Research Report 2016 1 Cancer Angiogenesis Inhibitor Market Overview 1.1 Product Overview and Scope of Cancer Angiogenesis Inhibitor 1.2 Cancer Angiogenesis Inhibitor Segment by Type 1.2.1 Global Production Market Share of Cancer Angiogenesis Inhibitor by Type in 2015 1.2.2 Type I 1.2.3 Type II 1.2.4 Type III 1.3 Cancer Angiogenesis Inhibitor Segment by Application 1.3.1 Cancer Angiogenesis Inhibitor Consumption Market Share by Application in 2015 1.3.2 Application 1 1.3.3 Application 2 1.3.4 Application 3 1.4 Cancer Angiogenesis Inhibitor Market by Region 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 Europe Status and Prospect (2011-2021) 1.4.3 China Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value) of Cancer Angiogenesis Inhibitor (2011-2021) 7 Global Cancer Angiogenesis Inhibitor Manufacturers Profiles/Analysis 7.1 Biocon 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.1.3 Biocon Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Allergan 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.2.3 Allergan Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 CASI Pharmaceuticals 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.3.3 CASI Pharmaceuticals Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Novartis 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.4.3 Novartis Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 Pfizer 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.5.3 Pfizer Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 Roche 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.6.3 Roche Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 Celgene Corporation 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.7.3 Celgene Corporation Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 Levolta Pharmaceuticals 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.8.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 Philogen 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.9.3 Philogen Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 Mabtech 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.10.3 Mabtech Cancer Angiogenesis Inhibitor Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview
Vallhov H.,Karolinska Institutet |
Kupferschmidt N.,Uppsala University |
Gabrielsson S.,Karolinska Institutet |
Paulie S.,Mabtech Ab |
And 3 more authors.
Small | Year: 2012
Alum is the most frequently used adjuvant today, primarily inducing Th2 responses. However, Th1-type responses are often desirable within immune therapy, and therefore the development of new adjuvants is greatly needed. Mesoporous silica particles with a highly ordered pore structure have properties that make them very interesting for future controlled drug delivery systems, such as controllable particle and pore size; they also have the ability to induce minor immune modulatory effects, as previously demonstrated on human-monocyte-derived dendritic cells (MDDCs). In this study, mesoporous silica particles are shown to be efficiently engulfed by MDDCs within 2 h, probably by phagocytic uptake, as seen by confocal microscopy and transmission electron microscopy. A co-culture protocol is developed to evaluate the capability of MDDCs to stimulate the development of naïve CD4+ T cells in different directions. The method, involving ELISpot as a readout system, demonstrates that MDDCs, after exposure to mesoporous silica particles (AMS-6 and SBA-15), are capable of tuning autologous naïve T cells into different effector cells. Depending on the size and functionalization of the particles added to the cells, different cytokine patterns are detected. This suggests that mesoporous silica particles can be used as delivery vehicles with tunable adjuvant properties, which may be of importance for several medical applications, such as immune therapy and vaccination. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Jahnmatz M.,Swedish Institute for Communicable Disease Control |
Kesa G.,Mabtech AB |
Netterlid E.,Swedish Institute for Communicable Disease Control |
Buisman A.-M.,National Institute for Public Health and the Environment |
And 2 more authors.
Journal of Immunological Methods | Year: 2013
B-cell responses after infection or vaccination are often measured as serum titers of antigen-specific antibodies. Since this does not address the aspect of memory B-cell activity, it may not give a complete picture of the B-cell response. Analysis of memory B cells by ELISpot is therefore an important complement to conventional serology. B-cell ELISpot was developed more than 25. years ago and many assay protocols/reagents would benefit from optimization. We therefore aimed at developing an optimized B-cell ELISpot for the analysis of vaccine-induced human IgG-secreting memory B cells. A protocol was developed based on new monoclonal antibodies to human IgG and biotin-avidin amplification to increase the sensitivity. After comparison of various compounds commonly used to in vitro-activate memory B cells for ELISpot analysis, the TLR agonist R848 plus Interleukin (IL)-2 was selected as the most efficient activator combination. The new protocol was subsequently compared to an established protocol, previously used in vaccine studies, based on polyclonal antibodies without biotin avidin amplification and activation of memory B-cells using a mix of antigen, CpG, IL-2 and IL-10. The new protocol displayed significantly better detection sensitivity, shortened the incubation time needed for the activation of memory B cells and reduced the amount of antigen required for the assay. The functionality of the new protocol was confirmed by analyzing specific memory B cells to five different antigens, induced in a limited number of subjects vaccinated against tetanus, diphtheria and pertussis. The limited number of subjects did not allow for a direct comparison with other vaccine studies. Optimization of the B-cell ELISpot will facilitate an improved analysis of IgG-secreting B cells in vaccine studies. © 2013 Elsevier B.V.
Feldoto Z.,Swedish Institute for Surface Chemistry |
Lundin M.,Swedish Institute for Surface Chemistry |
Braesch-Andersen S.,Mabtech AB |
Blomberg E.,Swedish Institute for Surface Chemistry
Journal of Colloid and Interface Science | Year: 2011
The binding of immunogloblulins (IgG) (mouse monoclonal recognizing IFNγ) on precoated polystyrene or silica surfaces by the layer-by-layer technique has been investigated with QCM-D and DPI. The aim of the work was to increase the sensitivity of the conventional enzyme-linked immunosorbent spot (ELISpot) assay. The polyelectrolytes used to build the multilayers were poly(allylamine hydrochloride) (PAH)/poly(sodium 4-styrenesulfonate) (PSS) alternately adsorbed from 150. mM NaCl. The multilayer build up is linear and the internal structure of the PAH/PSS multilayer is compact and rigid as observed by low relative water content (20-25%) and high layer refractive index (n∼ 1.5) after the formation of five bilayers. Incorporation of IgG within the PAH/PSS multilayer did not give rise to overcharging and did not affect the linear build up. ELISpot test on PAH/PSS multilayer modified polystyrene wells showed that the cytokine response was significantly smaller than on the regular PVDF backed polystyrene wells. This may be due to the compact and rigid nature of the PAH/PSS multilayer, which does not allow formation of the kind of three dimensional support needed to achieve bioactive IgG binding to the surface. Immunological tests of the polyelectrolyte multilayers in the absence of IgG showed that PSS terminated PAH/PSS multilayer did not induce any cytokine response whereas PAH terminated did, which suggests that PSS totally covers the surface from the cells point of view. © 2010 Elsevier Inc.